Mepidental

Mepivacaine, the active ingredient in Mepidental, is a local anesthetic presented as a sterile solution for infiltration and perineural use. It provides reversible nerve blockade for dental work, minor surgeries and peripheral nerve block procedures in adult patients. GNH USA supplies Mepidental as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepivacaine is a local anesthetic used to achieve reversible nerve blockade for procedures involving the oral cavity, minor surgery and regional nerve blocks. - Dental procedures: provides local anesthesia for tooth extractions, restorations and periodontal surgery. - Minor surgical procedures: enables analgesia for skin suturing, biopsies and small soft‑tissue operations. - Peripheral nerve blocks: facilitates regional anesthesia for limb surgeries and postoperative pain control.

Mepivacaine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient tingling or numbness at the injection site. - Mild swelling or erythema around the administered area. - Temporary dizziness or light‑headedness. - Mild headache. - Nausea.

Serious or Rare Side Effects: - Allergic reaction, including anaphylaxis. - Cardiac arrhythmias or conduction disturbances. - Methemoglobinemia (rare). - Central nervous system toxicity such as seizures. - Persistent numbness or paresthesia beyond the expected duration.

When using Mepivacaine, clinicians should observe several safety measures to minimise risk. - Assess patient allergy history: verify no known hypersensitivity to amide‑type local anesthetics. - Use the lowest effective concentration: limit systemic absorption and toxicity. - Avoid intravascular injection: aspirate before depositing the solution. - Monitor cardiac status in patients with pre‑existing conduction disorders. - Store at room temperature: keep in the original container, protect from light and moisture.

Mepivacaine can interact with other medications, requiring careful assessment before administration.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase cardiotoxicity. - Beta‑blockers combined with epinephrine‑containing solutions: risk of severe bradycardia. - Monoamine oxidase inhibitors (MAOIs): potential for prolonged anesthetic effect.

Moderate Interactions (Monitor Closely): - Concurrent use of other local anesthetics: cumulative toxicity risk. - CYP450 inhibitors (e.g., erythromycin): may affect metabolism and plasma levels. - Diuretics: may alter plasma protein binding and increase free drug concentration.